Grail Inc. Investors Face Critical Deadline in Cancer Trial Lawsuit

San Diego, Tuesday, 23 June 2026.
Grail Inc. shareholders who bought shares between May 2025 and February 2026 could join a class-action lawsuit over alleged misleading statements about its NHS-Galleri cancer trial. The lawsuit claims the company concealed critical flaws, including the trial’s failure to meet its primary endpoint—a statistically significant reduction in late-stage cancers. Investors have until August 4, 2026, to seek lead plaintiff status, with law firms racing to secure claimants after Grail’s stock plunged over 50% on the trial’s disappointing results.